Related Experiment Videos
Does digitalis work in chronic heart failure? The end of a 200-year-old controversy
1Department of Medicine, Mount Sinai School of Medicine, City University of New York, New York.
Insights
Digitalis effectively treats chronic heart failure with systolic dysfunction. However, it should be combined with diuretics and ACE inhibitors for optimal fluid balance, reduced mortality, and improved outcomes in heart failure management.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic heart failure (CHF) with left ventricular systolic dysfunction (LVSD) is a significant clinical challenge.
- Digitalis has been investigated for its role in managing CHF.
Observation:
- Modern controlled trials in well-defined patient groups provide robust evidence for digitalis efficacy.
- Digitalis is well-tolerated in patients with LVSD.
Findings:
- Digitalis alone is insufficient for comprehensive heart failure management.
- Diuretics are necessary to manage fluid retention and maintain sodium balance.
- Angiotensin-converting enzyme (ACE) inhibitors are crucial for reducing morbidity and mortality.
Implications:
- A combination therapy including digitalis, diuretics, and ACE inhibitors is recommended for optimal CHF management.
- This integrated approach addresses both symptomatic relief and long-term prognosis in heart failure patients.
- Optimizing heart failure treatment requires a multi-drug strategy tailored to specific pathophysiological aspects.
Abstract:
Controlled trials using modern methods of assessment in well-defined groups of patients have now convincingly demonstrated that digitalis is an effective and well-tolerated drug in patients with chronic heart failure who have left ventricular systolic dysfunction. These encouraging findings concerning digitalis, however, should not be construed to suggest that the drug should be used alone in the treatment of heart failure. Digitalis cannot adequately control the fluid retention seen in most patients with chronic heart failure; diuretics should be added to maintain sodium balance. Digitalis has not been shown to prolong life in chronic heart failure; converting-enzyme inhibitors should be added to reduce morbidity and mortality. All three drugs should be used together in the management of patients with this disorder.